WO2003082906A3 - Neurotrophe und neuroprotektive peptide - Google Patents

Neurotrophe und neuroprotektive peptide Download PDF

Info

Publication number
WO2003082906A3
WO2003082906A3 PCT/AT2003/000065 AT0300065W WO03082906A3 WO 2003082906 A3 WO2003082906 A3 WO 2003082906A3 AT 0300065 W AT0300065 W AT 0300065W WO 03082906 A3 WO03082906 A3 WO 03082906A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
disease
diseases
peptides
amino acids
Prior art date
Application number
PCT/AT2003/000065
Other languages
English (en)
French (fr)
Other versions
WO2003082906A2 (de
Inventor
Manfred Windisch
Original Assignee
Jsw Res Forschungslabor Gmbh
Manfred Windisch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jsw Res Forschungslabor Gmbh, Manfred Windisch filed Critical Jsw Res Forschungslabor Gmbh
Priority to AU2003212074A priority Critical patent/AU2003212074A1/en
Priority to NZ535623A priority patent/NZ535623A/en
Priority to EP03707885A priority patent/EP1499636A2/de
Priority to CA002480633A priority patent/CA2480633A1/en
Priority to JP2003580370A priority patent/JP2006508022A/ja
Priority to US10/509,095 priority patent/US20060036073A1/en
Publication of WO2003082906A2 publication Critical patent/WO2003082906A2/de
Publication of WO2003082906A3 publication Critical patent/WO2003082906A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Beschrieben werden neue Peptide, deren Einzelbestandteile L-Aminosäuren oder D-Aminosäuren sind. Diese Peptide kommen als Wirkstoffe in Arzneimitteln zur Anwendung bei der Therapie von Erkrankungen, bei denen das vermehrte Auftreten von freien Radikalen eine pathophysiologische Rolle spielt, oder bei der Therapie von Erkrankungen mit akuter Hypoxie oder Ischämie in einem Organsystem des Körpers, insbesondere im Zentralnervensystem, oder bei der Therapie von Eisenspeichererkrankungen, wie der Hallervorden-Spatz'schen Erkrankung, oder bei der Therapie neurodegenerativer Erkrankungen, insbesondere der Alzheimer'schen Erkrankung, der Lewy Body Variante der Alzheimer'schen Erkrankung, der Parkinson'schen Erkrankung, der Multisystem Atrophie, der Lewy Body Demenz oder der Huntington's Chorea, und allen diesen neurodegenerativen Erkrankungen ähnlichen Zustandsbildern.
PCT/AT2003/000065 2002-03-28 2003-03-10 Neurotrophe und neuroprotektive peptide WO2003082906A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2003212074A AU2003212074A1 (en) 2002-03-28 2003-03-10 Neurotrophic and neuroprotective peptides
NZ535623A NZ535623A (en) 2002-03-28 2003-03-10 Peptides, 4-14 amino acids in length, for treating degenerative conditions of the CNS
EP03707885A EP1499636A2 (de) 2002-03-28 2003-03-10 Neurotrophe und neuroprotektive peptide
CA002480633A CA2480633A1 (en) 2002-03-28 2003-03-10 Neurotrophic and neuroprotective peptides
JP2003580370A JP2006508022A (ja) 2002-03-28 2003-03-10 神経栄養性および神経保護性ペプチド
US10/509,095 US20060036073A1 (en) 2002-03-28 2003-03-10 Neurotrophic and neuroprotective peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0049502A AT500282A3 (de) 2002-03-28 2002-03-28 Neurotrophe und neuroprotektive peptide
ATA495/2002 2002-03-28

Publications (2)

Publication Number Publication Date
WO2003082906A2 WO2003082906A2 (de) 2003-10-09
WO2003082906A3 true WO2003082906A3 (de) 2004-11-25

Family

ID=28458152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2003/000065 WO2003082906A2 (de) 2002-03-28 2003-03-10 Neurotrophe und neuroprotektive peptide

Country Status (8)

Country Link
US (1) US20060036073A1 (de)
EP (1) EP1499636A2 (de)
JP (1) JP2006508022A (de)
AT (1) AT500282A3 (de)
AU (1) AU2003212074A1 (de)
CA (1) CA2480633A1 (de)
NZ (1) NZ535623A (de)
WO (1) WO2003082906A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012256A2 (en) * 2004-06-29 2006-02-02 Aventis Pharmaceuticals Inc. Fkbp binding composition and pharmaceutical use thereof
WO2007126111A1 (ja) * 2006-04-28 2007-11-08 Kagoshima University アミロイドβ線維化阻害ペプチド
AT504553B1 (de) * 2006-12-06 2008-09-15 Jsw Res Forschungslabor Gmbh Peptidomimetika aus rechtsdrehenden aminosäuren sowie diese enthaltende arzneimittel zur behandlung von neurodegenerativen erkrankungen
CN102348720A (zh) 2009-03-09 2012-02-08 雷蒙特亚特特拉维夫大学有限公司 预防和治疗神经退行性疾病的组合物和方法
JP5664992B2 (ja) * 2009-08-26 2015-02-04 国立大学法人名古屋大学 細胞特異的ペプチド及びその用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182356A2 (de) * 1984-11-19 1986-05-28 The Montefiore Hospital Association of Western Pennsylvania Nährstoffzusammensetzungen
WO2000020020A2 (en) * 1998-10-06 2000-04-13 The Regents Of The University Of California Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
WO2001060794A2 (en) * 2000-02-18 2001-08-23 The Regents Of The University Of California Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
WO2002004482A1 (en) * 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0182356A2 (de) * 1984-11-19 1986-05-28 The Montefiore Hospital Association of Western Pennsylvania Nährstoffzusammensetzungen
WO2000020020A2 (en) * 1998-10-06 2000-04-13 The Regents Of The University Of California Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
WO2001060794A2 (en) * 2000-02-18 2001-08-23 The Regents Of The University Of California Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
WO2002004482A1 (en) * 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAROOSHIAN A V ET AL: "Thin-layer chromatographic determination of the optical purity of labeled amino acids via dipeptide formation.", ANALYTICAL BIOCHEMISTRY. OCT 1972, vol. 49, no. 2, October 1972 (1972-10-01), pages 602 - 606, XP002294070, ISSN: 0003-2697 *
BUCHT G ET AL: "Optimising the signal peptide for glycosyl phosphatidylinositol modification of human acetylcholinesterase using mutational analysis and peptide-quantitative structure-activity relationships.", BIOCHIMICA ET BIOPHYSICA ACTA. 18 MAY 1999, vol. 1431, no. 2, 18 May 1999 (1999-05-18), pages 471 - 482, XP002294071, ISSN: 0006-3002 *
GUENTHER K ET AL: "THIN-LAYER CHROMATOGRAPHIC SEPARATION OF STEREOISOMERIC DIPEPTIDES", ANGEWANDTE CHEMIE INTERNATIONAL EDITION IN ENGLISH, vol. 25, no. 3, 1986, pages 278 - 279, XP002294072, ISSN: 0570-0833 *
HASHIMOTO M ET AL: "OXIDATIVE STRESS INDUCES AMYLOID-LIKE AGGREGATE FORMATION OF NACP/ALPHA-SYNUCLEIC IN VITRO", NEUROREPORT, RAPID COMMUNICATIONS OF OXFORD, OXFORD, GB, vol. 10, no. 4, 17 March 1999 (1999-03-17), pages 717 - 721, XP000891964, ISSN: 0959-4965 *
IWAI, AKIHIKO ET AL: "Precursor protein of non-A.beta. component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system", NEURON , 14(2), 467-75 CODEN: NERNET; ISSN: 0896-6273, 1995, XP002294068 *
LEFTHERIS, K. ET AL: "Peptide based P21ras farnesyl transferase inhibitors: systematic modification of the tetrapeptide CA1A2X motif", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 4(7), 887-92 CODEN: BMCLE8; ISSN: 0960-894X, 1994, XP002294069 *

Also Published As

Publication number Publication date
CA2480633A1 (en) 2003-10-09
US20060036073A1 (en) 2006-02-16
AT500282A2 (de) 2005-11-15
WO2003082906A2 (de) 2003-10-09
EP1499636A2 (de) 2005-01-26
AT500282A3 (de) 2006-06-15
JP2006508022A (ja) 2006-03-09
AU2003212074A1 (en) 2003-10-13
NZ535623A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
SG163567A1 (en) Treatment of tumors
IL213319A (en) Polylysis peptides for use in the treatment of bacterial infections
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
WO2006014570A3 (en) Purified amphilic peptide compositions and uses thereof
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
WO2006031811A3 (en) Glycopegylated interferon alpha
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
EP2455461A3 (de) Lipasevarianten zur pharmazeutischen Verwendung
EP1897550A3 (de) Prodrugs von exzitatorischen Aminosäuren
WO2002083065A3 (en) Peptide antiangiogenic drugs
EP2039367A4 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2002056833A3 (en) Preparation of a therapeutic composition
WO2002036614A3 (en) Peptides for use in the treatment of alzheimer's disease
WO2003082906A3 (de) Neurotrophe und neuroprotektive peptide
ATE389013T1 (de) Faktor x-analoge mit verbesserter fähigkeit zur aktivierung
WO2010057275A8 (en) Cyclic peptides and uses thereof
WO2004050685A3 (en) Antifungal therapeutic agents
CA2445048A1 (en) Preparations containing afamin for treating oxidative stress-induced neurogenerative disease
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
EP2143730A3 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
WO2007101948A3 (fr) Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003707885

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 090652003

Country of ref document: AT

Date of ref document: 20031009

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 90652003

Country of ref document: AT

Ref document number: 535623

Country of ref document: NZ

Ref document number: 2480633

Country of ref document: CA

Ref document number: 2003580370

Country of ref document: JP

Ref document number: 2003212074

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 01458/KOLNP/2004

Country of ref document: IN

Ref document number: 1458/KOLNP/2004

Country of ref document: IN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2003707885

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006036073

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10509095

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10509095

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003707885

Country of ref document: EP